CUTIA-B total transfer market value is HKD 91.5584 million, accounting for 7.07%, with 25.7205 million shares transferred from Morgan Stanley Hong Kong SecuritiesZhitong·Jun 4 at 07:25 PM02487-7.53%
CUTIA's self-developed local anesthetic cream has been approved for market launch by the mainland drug regulatory authorityetnet·May 6 at 06:56 PM02487-7.53%510660-2.73%
Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology PortfolioTip Ranks·May 6 at 06:55 PM02487-7.53%
CUTIA-B: CU-30101 (Topical Lidocaine and Dincaine Cream) has obtained marketing authorization from the National Medical Products AdministrationZhitong·May 6 at 05:45 PM02487-7.53%
FIDELITY CHINA SPECIAL SITUATIONS PLC increased its holdings of CUTIA-B by 30,600 shares at a price of HKD 4.6041 per shareZhitong·Apr 28 at 07:41 AM02487-7.53%
Understanding the Market | CUTIA-B rises over 3% CU-20101 (Injectable Type A Botulinum Toxin) completes Phase III clinical trial in ChinaZhitong·Apr 13 at 12:41 AM520690-1.29%512010-1.76%
CUTIA-B: CU-20101 (Injectable Type A Botulinum Toxin) used for improving moderate to severe glabellar lines has completed Phase III clinical trials in ChinaZhitong·Apr 12 at 07:22 PM159506-77.00%159892-1.11%
CUTIA-B released its annual performance, with a loss attributable to shareholders of 340 million yuan, a year-on-year decrease of 21.58%Zhitong·Mar 24 at 03:37 AM02487-7.53%159316-1.44%
CUTIA's annual loss narrowed to 340 million yuan, and no dividend will be distributedetnet·Mar 24 at 03:35 AM159849-3.08%588130-4.49%
"Performance" CUTIA's annual loss narrowed to 340 million RMB, no dividend declaredAASTOCKS·Mar 24 at 03:32 AM159992-3.21%512290-2.71%
Fidelity International increased its holdings in CUTIA-B by 1.7932 million shares at a price of HKD 5.01 per shareZhitong·Mar 16 at 06:01 AM02487-7.53%
CUTIA-B: CU-40104 (topical dutasteride formulation) new drug clinical trial application has obtained implied approval for clinical trials from the National Medical Products AdministrationZhitong·Mar 15 at 07:33 PM520690-1.29%513060-1.49%
CUTIA CU-40104 for the treatment of androgenetic alopecia has received implied approval from the mainland drug regulatory authorityetnet·Mar 15 at 07:19 PM159837-2.70%513700-1.55%
CUTIA-B shareholders transferred their shares from Citibank to Morgan Stanley Hong Kong Securities, with a transfer value of HKD 122 millionZhitong·Jan 26 at 06:57 PM159892-1.11%159506-77.00%
